MTI Appoints David Chang as New CEO

Metabolomic Technologies Inc. announces that it has appointed David Chang as Chief Executive Officer as of May 1st, 2017. Dr. Chang replaces Reg Joseph as CEO. He brings to the position 15 years experience managing SMEs and commercializing research projects. As the previous Chief Operating Officer of MTI, Dr. Chang oversaw the development of PolypDx™ from the research lab to market, and has established MTI as a respected and award-winning innovator.